Back

Molecular mechanism of SARS-Cov-2 components caused ARDS in murine model

Gu, T.; Zhao, S.; Jin, G.; Song, M.; Zhi, Y.; Zhao, R.; Ma, F.; Zheng, Y.; Wang, K.; Liu, H.; Xin, M.; Li, X.; Dong, C. D.; Liu, K.; Dong, Z.

2020-06-07 pathology
10.1101/2020.06.07.119032 bioRxiv
Show abstract

COVID-19 has become a major challenge to global health, and until now, no efficient antiviral agents have been developed. The SARS-CoV-2 infection is characterized by pulmonary and systemic inflammation in severe patients, and acute respiratory distress syndrome (ARDS) caused respiratory failure contributes to most mortalities. There is an urgent need for developing effective drugs and vaccines against SARS-CoV-2 and COVID-19 caused ARDS. However, most researchers cannot perform SARS-CoV-2 related researches due to lacking P3 or P4 facility. We developed a non-infectious, highly safety, time-saving SARS-CoV-2 components induced murine model to study the SARS-CoV-2 caused ARDS and cytokine storm syndrome (CSS). We also investigated mAbs and inhibitors which potentially neutralize the pro-inflammatory phenotype of COVID-19, and found that anti-IL-1, anti-IL-6, anti-TNF, anti-GM-CSF mAbs, p38 inhibitor, and JAK inhibitor partially relieved CSS. Besides, anti-IL-6, anti-TNF, anti-GM-CSF mAbs and inhibitors of p38, ERK, and MPO somewhat reduced neutrophilic alveolitis in the lung. In all, we established the murine model mimic of COVID-19, opening a biosafety and less time-consuming avenue for clarifying the mechanism of ARDS and CSS in COVID-19 and developing the therapeutic drugs.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Cell Discovery
54 papers in training set
Top 0.1%
26.6%
2
International Immunopharmacology
15 papers in training set
Top 0.1%
10.7%
3
National Science Review
22 papers in training set
Top 0.1%
8.6%
4
Science Bulletin
22 papers in training set
Top 0.1%
7.4%
50% of probability mass above
5
Protein & Cell
25 papers in training set
Top 0.4%
4.5%
6
Frontiers in Medicine
113 papers in training set
Top 1%
4.3%
7
Frontiers in Pharmacology
100 papers in training set
Top 1%
3.0%
8
Journal of Medical Virology
137 papers in training set
Top 1%
2.1%
9
PLOS ONE
4510 papers in training set
Top 47%
2.1%
10
Life Sciences
25 papers in training set
Top 0.4%
1.9%
11
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.7%
1.7%
12
Journal of Cellular Physiology
21 papers in training set
Top 0.3%
1.5%
13
eLife
5422 papers in training set
Top 45%
1.5%
14
Heliyon
146 papers in training set
Top 3%
1.3%
15
Advanced Therapeutics
15 papers in training set
Top 0.3%
0.9%
16
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.8%
0.8%
17
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.9%
0.8%
18
Cell Death Discovery
51 papers in training set
Top 1%
0.8%
19
Frontiers in Microbiology
375 papers in training set
Top 9%
0.8%
20
Theranostics
33 papers in training set
Top 2%
0.7%
21
Journal of Allergy and Clinical Immunology
25 papers in training set
Top 0.9%
0.7%
22
Respiratory Research
19 papers in training set
Top 0.6%
0.7%
23
JMIR Public Health and Surveillance
45 papers in training set
Top 4%
0.7%
24
Emerging Microbes & Infections
74 papers in training set
Top 2%
0.7%
25
British Journal of Cancer
42 papers in training set
Top 2%
0.7%
26
Immunology
29 papers in training set
Top 1%
0.7%
27
Cells
232 papers in training set
Top 7%
0.7%
28
International Journal of Molecular Sciences
453 papers in training set
Top 19%
0.5%
29
The Innovation
12 papers in training set
Top 1%
0.5%
30
Scientific Reports
3102 papers in training set
Top 80%
0.5%